NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch
KENILWORTH (NJ) (dpa-AFX) - Today s Daily Dose brings you news about Nektar s collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharma s strategic financing; and vTv Therapeutics initiation of a phase 1 multiple ascending dose study of HPP737.
Read on.
1. Nektar Teams Up With Merck
Nektar Therapeutics (NKTR) has entered into a clinical trial collaboration and supply agreement with Merck (MRK) for a Phase 2/3 study of Bempegaldesleukin in combination with KEYTRUDA for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck.